Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose.
We investigated the risk factors for graft-versus-host disease (GVHD) in 82 patients treated with donor lymphocyte infusions (DLI) using an escalating dose regimen for chronic myeloid leukaemia in relapse following conventional allografting. Two factors emerged as predictors of both acute and chronic GVHD: the infusion of male recipients with lymphocytes from a female donor and the interval between transplant and last DLI, but only the first remained significant at multivariate analysis. Surprisingly, lymphocyte dose did not influence the incidence of GVHD. Our results suggest that DLI can be given in large cell doses without increasing the risk of GVHD.
Fozza
C
C
Department of Haematology, Imperial College at Hammersmith Hospital, London, UK.
Szydlo
R M
RM
Abdel-Rehim
M M
MM
Nadal
E
E
Goldman
J M
JM
Apperley
J F
JF
Dazzi
F
F
D000328:Adult; D017252:CD3 Complex / Q000276:immunology; D005260:Female; D006086:Graft vs Host Disease; D006801:Humans; D007951:Leukemia, Myeloid / Q000276:immunology / Q000628:therapy*; D016015:Logistic Models; D017710:Lymphocyte Transfusion / Q000379:methods*; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D012008:Recurrence; D012074:Remission Induction; D012307:Risk Factors; D012737:Sex Factors; D013997:Time Factors; D014184:Transplantation, Homologous
D017252:CD3 Complex